Dravet Syndrome Market, Size, Share, Trends, Epidemiology Forecast till 2030

July 30 15:46 2020
Dravet Syndrome Market, Size, Share, Trends, Epidemiology Forecast till 2030

DelveInsight Business Research LLP
DelveInsight’s ‘Dravet Syndrome Market Insights, Epidemiology, and Market Forecast – 2030’ report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Dravet Syndrome (DS) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Dravet Syndrome is a severe form of epilepsy characterized by frequent, prolonged seizures often triggered by high body temperature (hyperthermia), developmental delay, speech impairment, ataxia, hypotonia, sleep disturbances, and other health problems.

 

Epidemiology Insights

  • The total incident population of Dravet Syndrome in 7MM in 2017 was 30,820 
  • The number of Dravet Syndrome patients in the United States in 2017 was 20,912
  • The number of Dravet Syndrome patients in Japan in 2017 was 2,766
  • The age-specific incidence in the US was highest among 4–8 years old, followed by 9–13 years old patients in 2017
  • The seizure-associated cases of Dravet Syndrome in Japan in 2017 was 1,369

 

Dravet Syndrome Market Insight

 

 

 

Dravet Syndrome Market Drivers

  • Increase in research activities
  • Increasing disease awareness

 

Dravet Syndrome Market Barriers

  • Disease Burden
  • Diagnostic Challenges
  • Comparatively Reduced Focus

 

 Request for sample pages

 

Table of contents

1 Key Insights

2 Executive Summary of Dravet Syndrome

3 SWOT Analysis for Dravet Syndrome

4 Dravet Syndrome Market Overview at a Glance

4.1 Market Share (%) Distribution of Dravet Syndrome in 2017

4.2 Market Share (%) Distribution of Dravet Syndrome in 2030

5 Dravet Syndrome: Disease Background and Overview

5.1 Introduction

5.2 Clinical Features of Dravet Syndrome

5.2.1 Epilepsy

5.2.2 Cognition

5.2.3 Movement disorders

5.2.4 Sudden Death

5.3 Genetics of Dravet Syndrome

5.3.1 Sodium Channel a1 Subunit Gene (SCN1A) and its association with Dravet Syndrome

5.3.2 Functional aspects of voltage gate sodium channel mutations

5.3.3 Detection of SCN1A mutations

5.3.4 Inheritance mode and pattern

5.3.5 Dravet Syndrome without SCN1A Alterations

5.4 Signs and Symptoms of Dravet Syndrome

5.5 Pathophysiology

5.6 Diagnosis of Dravet Syndrome

5.6.1 Differential diagnosis

6 Epidemiology and Patient Population

6.1 Key Findings

6.2 Total Incidence of Dravet Syndrome in 7MM

7 Country Wise-Epidemiology of Dravet Syndrome

8 United States

8.1 Assumptions and Rationale

8.2 Incident Population of Dravet Syndrome

8.3 Mutations associated with Dravet Syndrome

8.3.1 Incidence of Dravet Syndrome by Mutation Class

8.3.2 Incidence of Dravet Syndrome by Mutation Type

8.4 Seizure associated cases of Dravet Syndrome

8.5 Gender-specific Incidence of Dravet Syndrome

8.6 Age-specific Incidence of Dravet Syndrome

9 EU-5

9.1 Assumptions and Rationale

10 Germany

10.1 Incident Population of Dravet Syndrome

10.2 Mutations associated with Dravet Syndrome

10.2.1 Incidence of Dravet Syndrome by Mutation Class

10.2.2 Incidence of Dravet Syndrome by Mutation Type

10.3 Seizure associated cases of Dravet Syndrome

10.4 Gender-specific Incidence of Dravet Syndrome

10.5 Age-specific Incidence of Dravet Syndrome

11 France

11.1 Incident Population of Dravet Syndrome

11.2 Mutations associated with Dravet Syndrome

11.2.1 Incidence of Dravet Syndrome by Mutation Class

11.2.2 Incidence of Dravet Syndrome by Mutation Type

11.3 Seizure associated cases of Dravet Syndrome

11.4 Gender-specific Incidence of Dravet Syndrome

11.5 Age-specific Incidence of Dravet Syndrome

12 Italy

12.1 Incident Population of Dravet Syndrome

12.2 Mutations associated with Dravet Syndrome

12.2.1 Incidence of Dravet Syndrome by Mutation Class

12.2.2 Incidence of Dravet Syndrome by Mutation Type

12.3 Seizure associated cases of Dravet Syndrome

12.4 Gender-specific Incidence of Dravet Syndrome

12.5 Age-specific Incidence of Dravet Syndrome

13 Spain

13.1 Incident Population of Dravet Syndrome

13.2 Mutations associated with Dravet Syndrome

13.2.1 Incidence of Dravet Syndrome by Mutation Class

13.2.2 Incidence of Dravet Syndrome by Mutation Type.

13.3 Seizure associated cases of Dravet Syndrome

13.4 Gender-specific Incidence of Dravet Syndrome

13.5 Age-specific Incidence of Dravet Syndrome

14 United Kingdom

14.1 Incident Population of Dravet Syndrome

14.2 Mutations associated with Dravet Syndrome

14.2.1 Incidence of Dravet Syndrome by Mutation Class

14.2.2 Incidence of Dravet Syndrome by Mutation Type

14.3 Seizure associated cases of Dravet Syndrome

14.4 Gender-specific Incidence of Dravet Syndrome

14.5 Age-specific Incidence of Dravet Syndrome

15 Japan

15.1 Assumptions and Rationale

15.2 Incident Population of Dravet Syndrome

15.3 Mutations associated with Dravet Syndrome

15.3.1 Incidence of Dravet Syndrome by Mutation Class

15.3.2 Incidence of Dravet Syndrome by Mutation Type

15.4 Seizure associated cases of Dravet Syndrome

15.5 Gender-specific Incidence of Dravet Syndrome

15.6 Age-specific Incidence of Dravet Syndrome

16 Treatment of Dravet Syndrome

16.1 Current Treatment Practices

16.1.1 First-Line Therapies: Valproic Acid and Clobazam

16.1.2 Second-Line Therapies

16.1.3 Third Line of Therapies

16.2 Treatment Algorithm

17 Unmet Needs

18 Organizations contributing toward Dravet Syndrome

19 KOL’s Views: Dravet Syndrome

20 Case Studies

20.1 Anesthetic Management of Dravet Syndrome

20.2 Dravet Syndrome and Parkinsonism

21 Marketed Drugs

21.1 Diacomit: Biocodex

21.1.1 Drug Description

21.1.2 Mechanism of Action

21.1.3 Regulatory Milestones

21.1.4 Advantages and Disadvantages

21.1.5 Safety and Efficacy

21.2 Epidiolex: GW Pharmaceuticals

21.2.1 Drug Description

21.2.2 Mechanism of Action

21.2.3 Regulatory Milestones

21.2.4 Advantages and Disadvantages

21.2.5 Safety and Efficacy

22 Emerging Therapies

22.1 ZX-008: Zogenix

22.1.1 Product Description

22.1.2 Other Development Activities

22.1.3 Clinical Development

22.1.4 Safety and Efficacy

22.1 Soticlestat: Ovid Therapeutics

22.1.1 Product Description

22.1.2 Other Development Activities

22.1.3 Clinical Development

22.1.4 Safety and Efficacy

22.2 Ataluren: PTC Therapeutics

22.2.1 Product Description

22.2.2 Clinical Development

23 Dravet Syndrome: Seven Major Market Analysis

23.1 Key Findings

23.2 Total Market Size of Dravet Syndrome in 7MM

24 Market Outlook by Country

24.1 The United States: Market Outlook

24.2 United States Market Size

24.2.1 Total Market Size of Dravet Syndrome

24.2.2 Dravet Syndrome Market Size by Therapies

24.3 EU-5 Countries: Market Outlook

24.4 Germany Market Size

24.4.1 Total Market Size of Dravet Syndrome

24.4.2 Dravet Syndrome Market Size by Therapies

24.5 France Market Size

24.5.1 Total Market Size of Dravet Syndrome

24.5.2 Dravet Syndrome Market Size by Therapies

24.6 Italy Market Size

24.6.1 Total Market Size of Dravet Syndrome

24.6.2 Dravet Syndrome Market Size by Therapies

24.7 Spain Market Size

24.7.1 Total Market Size of Dravet Syndrome

24.7.2 Dravet Syndrome Market Size by Therapies

24.8 The United Kingdom Market Size

24.8.1 Total Market Size of Dravet Syndrome

24.8.2 Dravet Syndrome Market Size by Therapies

24.9 Japan: Market Outlook

24.10 Japan: Market Size

24.10.1 Total Market Size of Dravet Syndrome

24.10.2 Dravet Syndrome Market Size by Therapies

25 Market Drivers

26 Market Barriers

27 Appendix

28 Report Methodology

28.1 Sources Used

29 DelveInsight Capabilities

30 Disclaimer

31 About DelveInsight

 

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/